The Institute for Clinical and Economic Review (ICER) on Friday, March 13, posted two new draft scoping documents outlining planned reviews of bladder cancer treatments, as well as digital apps used for opioid use disorder.
According to a press release, ICER is planning to review nadofaragene firadenovec and oportuzumab monatox for the treatment of bladder cancer, and the digital app reSET-O by Pear Therapeutics.
A public comment period will remain open until 5 p.m. EST, April 2.
To read the scoping document for the bladder cancer treatments, click here.
To read the scoping document for the digital solutions, click here.